Home

Foldax has announced that the US Food and Drug Administration (FDA) has granted investigational device exemption IDE approval for the company to initiate a clinical study of its Tria biopolymer mitral surgical heart valve. The company anticipates the first use of its mitral valve in a human will take place in the coming weeks.

The mitral valve is the second of three Tria biopolymer heart valve products in the Foldax portfolio, and addresses a large unmet clinical need based on the prevalence of rheumatic fever worldwide.

The first of the company’s products—an aortic surgical heart valve—is currently enrolling a US clinical study as a result of FDA approval of an expanded study last October. The third valve product is a transcatheter aortic valve implant (TAVI), which is in the pre-clinical testing phase.

The Tria valves incorporate a new, proprietary biopolymer—LifePolymer—with valve designs intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants, Foldax said in a press release.

“There is a great need for a more durable mitral valve, as tissue valves tend to be much less durable in the mitral position than in the aortic position, yet there have been very few mitral valve clinical studies in the past decade,” stated Frank Shannon, chief of Cardiovascular Surgery at Beaumont Hospital in Royal Oak, USA and head of the Foldax Medical Advisory Board. “The Tria biopolymer valve offers the potential to be an important new therapeutic option with enhanced durability that is intended to allow patients to avoid taking the blood thinning medication required by mechanical valves.”

“We are gratified that the FDA has now approved two of our valves for clinical investigation. This latest approval is an important milestone in our mission to develop a portfolio of surgical and transcatheter biopolymer heart valves designed to last a lifetime,” stated Foldax CEO Frank Maguire. “We view the Tria mitral valve as a product with global appeal that is capable of meeting the durability needs of both advanced and developing countries, while addressing the consequences of rheumatic fever and challenges of managing mechanical valve-related anticoagulation therapy in developing regions.”

According to Foldax, Tria is also the first and only heart valve to be robotically manufactured, reducing variability and enabling high precision, repeatability and quality, while substantially improving the economics of heart valve manufacturing.

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua google bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua twitter bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua MySpace bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua LinkedIn bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua stumbleupon bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua icio bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua digg bài: Investigational device exemption granted for Tria bioloymer mitral valve

Chia sẽ qua yahoo bài: Investigational device exemption granted for Tria bioloymer mitral valve

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.